수의 및 동물용 백신 시장 : 제품 유형, 투여 경로, 대상 질환, 기술 플랫폼, 가수, 동물 유형, 유통 채널, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Veterinary/Animal Vaccines Market is projected to grow by USD 24.01 billion at a CAGR of 6.89% by 2032.

Veterinary and animal vaccines are a foundational pillar of preventive animal health, food security, and zoonotic disease control. They reduce morbidity and mortality in livestock and companion animals, support antimicrobial stewardship by lowering disease-driven antibiotic use, and help protect trade continuity in sectors where outbreaks can trigger movement restrictions, culling, and export bans.

Demand is being shaped by the rising global need for safe animal protein, intensifying biosecurity requirements, expanding companion animal ownership, and government-backed disease control programs. Core vaccine categories include live attenuated, inactivated, toxoid, subunit, recombinant, vector-based, DNA, and emerging RNA platforms used across cattle, swine, poultry, aquaculture, equine, and pet health applications.

The veterinary vaccines market is increasingly defined by speed, precision, and scalability. Manufacturers and animal health stakeholders are investing in thermostability, multivalent formulations, DIVA-compatible vaccines that help differentiate infected from vaccinated animals, and platform technologies that can be adapted faster when new variants or emerging pathogens appear.

Transformative Shifts in the Animal Vaccine Landscape

The veterinary vaccines landscape is moving from reactive outbreak response toward integrated disease prevention. Governments, producers, veterinarians, and pharmaceutical organizations are aligning vaccination with surveillance, diagnostics, biosecurity, and traceability. This shift is especially visible in transboundary animal diseases such as foot-and-mouth disease, avian influenza, African swine fever research programs, rabies, brucellosis, and peste des petits ruminants.

Another major shift is the growing importance of species-specific and production-system-specific immunization. Poultry and swine operations require high-volume, cost-efficient vaccination supported by hatchery automation and herd-level protocols, while cattle and aquaculture programs increasingly emphasize disease economics, regional pathogen pressure, and cold-chain reliability. In companion animal health, preventive vaccination remains central to veterinary practice as pet ownership rises and owners seek longer, healthier animal lifespans.

Innovation is also transforming competitive positioning. Recombinant and vector vaccines are gaining relevance where conventional approaches face safety, efficacy, or differentiation challenges. At the same time, regulatory expectations for potency, safety, pharmacovigilance, and manufacturing consistency are raising barriers to entry and rewarding participants with proven quality systems.

Cumulative Impact of Artificial Intelligence on Veterinary Vaccines

Artificial intelligence is beginning to reshape veterinary vaccine discovery, development, manufacturing, and field deployment. In research, AI-enabled bioinformatics can help identify antigen candidates, compare pathogen genomes, track mutations, and support epitope mapping. These capabilities are particularly relevant for rapidly evolving pathogens and for vaccines requiring strain updates based on surveillance data.

In clinical development and production, machine learning can improve trial design, batch analytics, quality monitoring, and yield optimization. AI tools also support predictive epidemiology by integrating farm-level, climate, movement, and diagnostic data to identify disease risk patterns. This can help animal health stakeholders prioritize vaccination campaigns and optimize inventory allocation.

The cumulative impact is not replacement of scientific validation, but acceleration of evidence generation. Veterinary vaccines still require controlled studies, regulatory review, safety monitoring, and real-world effectiveness data. However, AI can shorten decision cycles and improve precision when paired with validated diagnostics, robust datasets, and responsible governance.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is a high-priority region due to its large livestock population, major poultry and aquaculture industries, and continued investment in disease control infrastructure. China and India are central to regional demand, supported by large-scale animal protein production, dairy development, and government vaccination initiatives, while Japan, South Korea, and Australia emphasize high biosecurity standards, companion animal care, and advanced biologics oversight.

North America remains a mature and innovation-led region, supported by strong veterinary infrastructure, high companion animal spending, established livestock vaccination programs, and rigorous oversight from public veterinary biologics authorities in the United States and Canada. Latin America is closely tied to cattle, poultry, and swine production, with Brazil and Mexico playing important roles in commercial vaccination, rabies prevention, and export-oriented disease control.

Europe is shaped by stringent quality, pharmacovigilance, animal welfare, and food safety frameworks, with regional harmonization influencing regulatory access and post-authorization monitoring. The Middle East is increasing attention to livestock resilience, camel and small ruminant health, poultry biosecurity, and import controls, particularly in Gulf economies. Africa has substantial unmet need, with vaccination programs central to controlling diseases that affect pastoral livelihoods, food security, and zoonotic risk, including rabies, peste des petits ruminants, and other transboundary animal diseases.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN demand is supported by poultry, swine, aquaculture, and smallholder livestock systems that require scalable vaccination models, stronger cold chains, and regionally adapted disease surveillance. The GCC is focused on biosecurity, food import resilience, and vaccination needs for camels, sheep, goats, poultry, and companion animals, with public-sector procurement remaining important in animal health planning.

The European Union is a benchmark for regulatory quality, pharmacovigilance, traceability, and One Health alignment. Policy priorities around antimicrobial resistance and animal welfare reinforce the value of preventive immunization. BRICS countries represent a large share of global livestock production and animal protein consumption, making them strategically important for volume-based adoption, local manufacturing, technology transfer, and government-backed immunization programs.

The G7 countries lead in research intensity, premium companion animal care, advanced biologics manufacturing, and high-standard regulatory science, while NATO member countries share heightened attention to biosecurity, supply-chain resilience, and preparedness for animal disease events that could disrupt food systems. Across all groups, veterinary vaccines are increasingly viewed as strategic infrastructure rather than discretionary animal health products.

Key Country Insights Across Major Veterinary Vaccine Markets

The United States leads through advanced biologics regulation, strong pet healthcare demand, and integrated livestock health programs, while Canada benefits from high animal health standards and cross-border alignment in North American livestock trade. Mexico is a significant livestock and poultry market where vaccination supports productivity, rabies control, and export readiness. Brazil is one of the world's most important animal protein producers, making cattle, poultry, and swine vaccines essential to disease prevention, biosecurity, and market access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature veterinary networks with strong companion animal care and livestock disease prevention programs. Germany and France are also important centers for animal health research, quality systems, and biologics expertise. Russia's large livestock base creates demand for domestically supplied and regionally adapted vaccines, particularly for cattle, poultry, and swine.

China and India are pivotal because of livestock scale, poultry expansion, dairy development, aquaculture relevance, and government-led disease control priorities. Japan, Australia, and South Korea are characterized by high biosecurity expectations, technologically advanced veterinary services, and strong demand for quality-assured biologics. Australia's livestock export orientation and recognized disease-free status for several major pathogens make preventive animal health, quarantine systems, and surveillance especially important.

Actionable Recommendations for Veterinary Vaccine Industry Leaders

Industry leaders should prioritize platform-based vaccine development, stronger surveillance partnerships, and manufacturing flexibility. Recombinant, vector, and nucleic acid platforms can improve response speed, but success depends on validated efficacy, clear regulatory pathways, and scalable quality systems.

Organizations should localize strategies by species, disease burden, production model, and purchasing channel. High-volume livestock markets require affordability, reliability, and distribution strength, while companion animal markets reward veterinary trust, professional education, and clear owner communication.

Recommended actions include investing in thermostable formulations, expanding DIVA and multivalent portfolios, strengthening cold-chain visibility, using AI for surveillance-linked portfolio planning, and partnering with governments, universities, and producer organizations. Leaders should also integrate vaccine programs with diagnostics, biosecurity, and antimicrobial stewardship to demonstrate measurable value beyond product sales.

Research Methodology for Veterinary and Animal Vaccines Analysis

This executive summary is developed using a secondary research-led methodology aligned with market intelligence best practices. Inputs include publicly available information from animal health regulators, veterinary authorities, intergovernmental organizations, scientific literature, product approvals, disease control programs, vaccination guidelines, and trade-relevant biosecurity frameworks.

The analysis applies triangulation across demand drivers, disease epidemiology, regulatory structures, species-level use cases, technology platforms, and regional production systems. Emphasis is placed on verified themes rather than unsupported market sizing claims, ensuring that insights remain credible for strategic planning, market education, and executive decision-making.

Key assessment dimensions include vaccine type, route of administration, target species, disease area, end-user channel, regional policy environment, manufacturing capability, competitive innovation, and adoption constraints such as cold chain, cost, awareness, and field effectiveness.

Conclusion: Veterinary Vaccines as a One Health Growth Engine

Veterinary and animal vaccines are becoming more strategically important as the world confronts rising protein demand, zoonotic disease risk, antimicrobial resistance, and the economic impact of animal disease outbreaks. The sector is advancing from conventional vaccination models toward data-informed, platform-enabled, and regionally tailored prevention strategies.

Future progress will depend on scientific innovation, regulatory trust, field-proven efficacy, and equitable access. Organizations that combine strong biologics expertise with AI-enabled surveillance, resilient supply chains, and deep regional partnerships will be best positioned to address opportunities across livestock, aquaculture, and companion animal health.

As prevention becomes central to animal health economics and One Health policy, veterinary vaccines will remain a critical enabler of productivity, food security, trade stability, and public health protection.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Veterinary/Animal Vaccines Market, by Product Type

• 7.1. Live Attenuated Vaccines
• 7.2. Inactivated Vaccines
• 7.3. Subunit & Recombinant Vaccines
• 7.4. Viral Vector Vaccines

8. Veterinary/Animal Vaccines Market, by Route Of Administration

• 8.1. Parenteral
• 8.2. Oral
• 8.3. Topical

9. Veterinary/Animal Vaccines Market, by Disease Indication

• 9.1. Viral Diseases
  • 9.1.1. Rabies
  • 9.1.2. Foot-and-Mouth Disease
  • 9.1.3. Newcastle Disease
  • 9.1.4. Canine Parvovirus
  • 9.1.5. Canine Distemper
  • 9.1.6. Feline Panleukopenia
  • 9.1.7. Infectious Bovine Rhinotracheitis
• 9.2. Bacterial Diseases
  • 9.2.1. Brucellosis
  • 9.2.2. Leptospirosis
  • 9.2.3. Clostridial Infections
  • 9.2.4. Pasteurellosis
  • 9.2.5. Colibacillosis
• 9.3. Parasitic Diseases
• 9.4. Fungal Infections

10. Veterinary/Animal Vaccines Market, by Technology Platform

• 10.1. Conventional Vaccines
• 10.2. Advanced Vaccines
• 10.3. Novel Delivery Systems

11. Veterinary/Animal Vaccines Market, by Valency

• 11.1. Monovalent Vaccines
• 11.2. Multivalent Vaccines

12. Veterinary/Animal Vaccines Market, by Animal Type

• 12.1. Companion Animals
  • 12.1.1. Dogs
  • 12.1.2. Cats
  • 12.1.3. Horses
• 12.2. Food-Producing Animals
  • 12.2.1. Cattle
  • 12.2.2. Swine
  • 12.2.3. Poultry
  • 12.2.4. Sheep & Goats
  • 12.2.5. Aquaculture
• 12.3. Wildlife & Zoo Animals

13. Veterinary/Animal Vaccines Market, by Distribution Channel

• 13.1. Veterinary Clinics
• 13.2. Retail Pharmacies
• 13.3. Online Pharmacies

14. Veterinary/Animal Vaccines Market, by End User

• 14.1. Veterinary Hospitals & Clinics
• 14.2. Animal Farms & Production Units
• 14.3. Reference Laboratories
• 14.4. Research Institutes & Universities
• 14.5. Government & Public Health Agencies

15. Veterinary/Animal Vaccines Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Veterinary/Animal Vaccines Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Veterinary/Animal Vaccines Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Arko Corp.
• 19.2. Bimeda Biologicals Inc
• 19.3. Biogenesis Bago S.A.
• 19.4. Biogenesis Bago S.A.
• 19.5. Bioveta, a.s.
• 19.6. Boehringer Ingelheim International GmbH
• 19.7. Ceva Sante Animale
• 19.8. Dechra Pharmaceuticals PLC
• 19.9. Elanco Animal Health Incorporated
• 19.10. Endovac Animal Health
• 19.11. Hester Biosciences Limited
• 19.12. Hipra S.A.
• 19.13. Huvepharma, Inc.
• 19.14. Indian Immunologicals Limited
• 19.15. Jinyu Bio-technology Co., Ltd.
• 19.16. Kemin Industries, Inc.
• 19.17. Merck & Co., Inc.
• 19.18. MEVAC
• 19.19. Neogen Corporation
• 19.20. Nisseiken Co., Ltd.
• 19.21. Pfizer, Inc.
• 19.22. Phibro Animal Health Corporation
• 19.23. Qingdao Yebio Biological Engineering Co., Ltd.
• 19.24. SAN Group
• 19.25. Seppic by Air Liquide Healthcare
• 19.26. SK Bioscience
• 19.27. Vaxxinova
• 19.28. Virbac S.A.
• 19.29. Zoetis Inc.